您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > KC7F2
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
KC7F2
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
KC7F2图片
CAS NO:927822-86-4
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议
1g电议

产品介绍
理化性质和储存条件

Molecular Weight (MW)

570.38

Formula

C16H16Cl4N2O4S4

CAS No.

927822-86-4

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: 100 mg/mL (175.3 mM)

Water:<1 mg/mL

Ethanol:<1 mg/mL

Solubility (In vivo)

Chemical Name: N,N'-(disulfanediylbis(ethane-2,1-diyl))bis(2,5-dichlorobenzenesulfonamide)

InChi Key: REQLACDIZMLXIC-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H16Cl4N2O4S4/c17-11-1-3-13(19)15(9-11)29(23,24)21-5-7-27-28-8-6-22-30(25,26)16-10-12(18)2-4-14(16)20/h1-4,9-10,21-22H,5-8H2

SMILES Code: ClC1=C(S(NCCSSCCNS(C2=C(Cl)C=CC(Cl)=C2)(=O)=O)(=O)=O)C=C(Cl)C=C1

Synonyms

KC-7F2; KC 7F2; KC7F2
实验参考方法

In Vitro

In vitro activity: KC7F2 inhibits HRE-driven transcription and decreases HIF-1α protein levels in LN229-HRE-AP cells. KC7F2 shows a dose-response cytotoxicity with IC50 of approximately 15 to 25 μM in cancer cells MCF7, LNZ308, A549, U251MG, and LN229. In D54MG glioma cells, KC7F2 inhibits colony formation, especially under hypoxia. In hypoxic microglial cultures, KC7F2 downregulates the expression of TfR and DMT, and reduces the HIF-1α mediated iron accumulation.

Kinase Assay: Cells are incubated at 37°C in a humidified atmosphere containing 5% CO2 and 21% O2 (normoxia) or 1% O2 (hypoxia) in a hypoxia workstation. The LN229-HRE-AP reporter cell line for HIF transcriptional activity is created by stably transfecting LN229 cells with the pACN188 plasmid, which contains an alkaline phosphatase gene driven by six HREs derived from the VEGF gene.

Cell Assay: Cells (Human dermal microvascular endothelial cells and mouse neurons; MCF7, LNZ308, A549, U251MG, and LN229 cell lines) are seeded onto 96-well plates (4 × 103/well) and cultured under normoxic (21% O2) and hypoxic (1% O2) conditions with different concentrations of KC7F2 for 72 h or treated for various times with 20 μM KC7F2. For proliferation analysis, cells are fixed with 50% trichloroacetic acid for 1 h at 4°C, followed by staining with 0.4% sulforhodamine B dissolved in 1% acetic acid for 30 min at room temperature. Plates are washed five times with 1% acetic acid to remove unbound dye. Bound dye is dissolved by adding 10 mM unbuffered Tris base. Cell proliferation is calculated by measuring OD values at 564 nm using a spectrophotometer.

In Vivo

KC7F2 significantly reduces the latent period in the pentylenetetrazole kindling rat model and increases the rate of spontaneous recurrent seizures during the chronic stage in the lithium-pilocarpine rat model.

Animal model

In a rat epilepsy model, KC7F2 significantly shortened the latent period in the PTZ kindling model and increased the rate of spontaneous recurrent seizures during the chronic stage in the lithium-pilocarpine model

Formulation & Dosage


References

Clin Cancer Res. 2009 Oct 1;15(19):6128-36; Neuropharmacology. 2014 Feb;77:428-40; Synapse. 2014 Sep;68(9):402-9.

生物活性


KC7F2 inhibits HRE-driven transcription. Clin Cancer Res. 2009 Oct 1;15(19):6128-36.



Cytotoxicity analysis in response to KC7F2 treatment. Clin Cancer Res. 2009 Oct 1;15(19):6128-36.


KC7F2 reduces the protein levels of HIF-1α in cancer cell lines of different tissue origin and genetic background. Clin Cancer Res. 2009 Oct 1;15(19):6128-36.